| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
We had identified Angiotensin IV (AT4) receptor as a hypertension/diabetes specific gene through genetic DNA chip analysis. It is a component of the renin angiotensin system. At the same time, it is the same protein as insulin regulated aminopeptidase (IRAP). Thus it could be presumed that AT4 is a key molecule that mediate the blood pressure abnormality and carbohydrate dysregulation.
Accordingly we have established a high sensitivity measurement system for the AT4 with a monoclonal antibody method after polyclonal system. Actual measurements on clinical subjects revealed that the sAT4 values tended to be lower on hypertensive cases, obesity cases and dyslipidemic cases and that the sAT4 values were significantly low on CKD cases. Furthermore we revealed that a genetic variant of the AT4 associate the plasma concentrations.
|
